Indolent systemic mastocytosis (ISM) is one of the five subtypes of systemic mastocytosis, a condition characterized by the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In a study of 116 patients with systemic mastocytosis (SM), a rare mast cell disease, about 1 in 5 participants ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

For many common diseases, there is significant evidence documenting their natural history, clinical presentation, signs and symptoms, and real-world impact on people’s daily lives. However, data ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

In a study of 116 patients with systemic mastocytosis (SM), a rare mast cell disease, about 1 in 5 participants progressed to an advanced form of SM, incurring greater healthcare costs along the way.